Table 1 Demographic and baseline characteristics of study participants by sICH per mSITS-MOST criteria

Age (years)

65 (61–72)

64 (55–71)

0.153^a

 Male

21 (63.6)

824 (65.4)

0.854

 Female

12 (36.4)

436 (34.6)

DNT (min)

66 (55–95)

50 (35–69)

< 0.001^a

Onset-to-needle time (ONT) (min)

182 (143–215)

171 (140–195)

0.267^a

Baseline NIHSS

14 (10–18)

7 (4–12)

< 0.001^a

Hypertension, n (%)

19 (57.6)

734 (58.3)

1.000

Diabetes mellitus, n (%)

7 (21.2)

198 (15.7)

0.466

Dyslipidemia, n (%)

1 (3.0)

26 (2.1)

0.506

Coronary heart disease, n (%)

12 (36.4)

172 (13.7)

0.001

Atrial fibrillation, n (%)

6 (18.2)

89 (7.1)

0.060

Systolic blood pressure before thrombolysis, mm Hg

151 (145.5–155)

151 (140–164)

0.610^a

Diastolic blood pressure before thrombolysis, mm Hg

86 (83–95)

86 (80–94)

0.210^a

Smoking, n (%)

11 (33.3)

445 (35.3)

0.856

Alcohol consumption, n (%)

11 (33.3)

397 (31.5)

0.850

Blood glucose on admission (mmol/L)

9.1 (5.9–12.3)

8.3 (5.2–11.4)

0.045^a

Antiplatelet treatment pre-IVT, n (%)

7 (21.2)

146 (11.6)

0.178

Anticoagulant treatment pre-IVT, n (%)

1 (3.0)

19 (1.5)

0.244

Neutrophils ratio (%)^b

73.4 (63.2–81.4)

67.2 (61.0–73.0)

0.006^a

Platelet count (× 1000/mm³)

195.0 (170.3–231.5)

223.3 (192.0–248.0)

0.059^a

White blood cell (×1000/mm³)

9.0 (7.3–10.9)

7.95 (6.03–8.40)

0.004^a

LDL-C, mmol/L

2.89 (2.38–2.99)

2.97 (2.53–3.33)

0.155^a

 rtPA

26 (78.8)

1070 (84.9)

0.227

 urokinase

7 (21.2)

190 (15.1)

 No use

7 (21.2)

190 (15.1)

< 0.001

 0.9 mg/kg

26 (78.8)

602 (47.8)

 0.6 mg/kg

0 (0)

22 (1.7)

 50 mg/person

0 (0)

446 (35.4)

 No use

26 (78.8)

1070 (84.9)

0.281

 1 million units

6 (18.2)

173 (13.7)

 1.5 million units

1 (3.0)

17 (1.3)

 Atherothrombotic

18 (54.5)

972 (77.1)

< 0.001

 Small vessel disease

3 (9.1)

205 (16.3)

 Cardioembolism

10 (30.3)

60 (4.8)

 Unknown or other etiology

2 (6.1)

23 (1.8)